Latest News and Press Releases

ROSELAND, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a...

ROSELAND, N.J., Aug. 28, 2018 (GLOBE NEWSWIRE) -- On August 20, 2018, Novo Nordisk A/S (Novo Nordisk) announced the headline results from PIONEER 5, a phase 3a trial with oral semaglutide in adults...

ROSELAND, N.J., June 29, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trial, PIONEER 3, with oral semaglutide, a once-daily oral formulation...

ROSELAND, N.J., June 21, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trials, PIONEER 4 and 7, with oral semaglutide, a once-daily oral...

ROSELAND, N.J., May 31, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk (NYSE:NVO) announced Tuesday the completion of the second phase 3a trial, PIONEER 2, with oral semaglutide, a once-daily oral...

ROSELAND, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that its non-prescription medical food product, Eligen B12, has earned the coveted...

ROSELAND, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk...

ROSELAND, N.J., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced today the successful completion of the first phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation...

ROSELAND, N.J., Aug. 11, 2017 (GLOBE NEWSWIRE) -- The Board of Directors of Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that the Company intends to voluntarily terminate its reporting...

ROSELAND, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the first quarter ended March 31, 2017, and how to access today’s...